Clinical Trial Update: One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL [NA]

View source ↗

Summary

Recruitment is ongoing for JCXH-213 to evaluate its safety, tolerability, and efficacy in patients with recurrent or refractory B-cell non-Hodgkin lymphoma. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• JCXH-213

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory | NA | Status: RECRUITING